1、Overcoming Tumor Heterogeneity, Unlocking New Dimensions of Authentic Clinical Drug Efficacy Prediction

Traditional commercial cell lines struggle to mimic patient tumor heterogeneity, resulting in a disconnect between preclinical drug efficacy prediction and actual clinical response. Leveraging a Chinese primary tumor cell bank, Jennio Bio provides primary tumor cell line construction services that highly preserve patient-specific characteristics, helping pharmaceutical companies achieve precise alignment from in vitro screening to clinical translation and reduce R&D risks.

2、Service Overview

Positioning: Primary tumor cell lines are the core of preclinical drug screening, directly reflecting the biological characteristics and drug sensitivity of patient tumors.

Solution: Jennio Bio isolates and cultures primary cells from surgical/biopsy samples through standardized processes, preserving the gene expression profile, pathological features, and drug response characteristics of the original tumor, providing pharmaceutical companies with highly predictive in vitro drug sensitivity models.

Core Objectives

• Stable Primary Cell Line Establishment: Complete primary cell line construction within 10–15 weeks, with stable passage for over 20 generations.
• Enhanced Clinical Relevance: Cell STR identification (9-locus one-step method) + histopathological verification, ensuring >90% consistency between the model and the source tumor.

3、Our Services

1. 1.Primary Tumor Cell Line Establishment

• Sample Types: Surgically resected tissue, needle biopsy samples, pleural effusion and ascites, etc. (dry ice transportation, viable preservation solution ensures activity).
• Technical Process:

Tissue dissociation → PDX expansion → Primary culture (CR technology) → Cell expansion → Cryopreservation.

• Deliverables: P3–P5 cell lines (with STR identification report, cell morphology images, growth curve).
• Featured Cancer Types: Covers high-incidence tumors including lung cancer (76% tumor formation rate), liver cancer (48%), colorectal cancer (77%), etc.

2. In Vitro Drug Sensitivity Testing Platform

Testing Items：

Customized Protocols: Support single-agent / combination therapy, dose-time gradient design, provide dose-response curves and combination index analysis.

3. 3.Supporting Model Integration
   • PDX Model Integration: Parallel efficacy verification of primary cells and PDX models from the same source, enabling in vitro-in vivo data cross-validation.
   • 3D Organoid Co-culture: Simulates tumor microenvironment, improves accuracy of drug response prediction.

4、Technology Platform and Advantages

1. 1.Core Technologies and Facilities

• CR Primary Culture Technology
• GMP-grade Cell Bank: Class 10,000 clean culture room + BSL-2 laboratory, ensuring no mycoplasma/cross-contamination.
• High-Throughput Automated Platform: High-throughput liquid handling system (>500 samples processed daily), supports 96-well plate screening.

2. 2.Differentiated Advantages

• Chinese Population Specificity: 100+ Chinese primary tumor cell bank, covering rare cancer types.
• Data Traceability: Open access to original data for traceability.
• Cost Efficiency: Line establishment success rate >70%, 30% faster than traditional methods.

5、Service Process

Standardized Four-Phase Management：

1. Requirement Confirmation (1–2 working days): Clarify sample types, testing indicators, and delivery requirements.
2. Sample Processing (3–5 days): Sample activation, PDX animal inoculation.
3. PDX Tumor Formation (4–8 weeks): Primary isolation, culture and quality control (STR identification).
4. Drug Sensitivity Assay (10–15 days): Perform testing per protocol, interim data report.
5. Report Delivery (5 days): Provide raw data, statistical charts and final report (PDF + Excel).
6. Transparent Collaboration: Customer-exclusive online portal for real-time progress tracking, supports remote video audit.

6、Quality Control and Compliance

Quality Control Standards

• Cell viability >90% (Trypan blue assay).
• Sterility/Mycoplasma testing (PCR method, compliant with ISO 9001).

Data Compliance

• Experimental operations comply with GLP-aligned standards (not certified but implemented).
• Raw data double-checked + third-party bioinformatics cross-validation.

7、Case Studies

Case 1: Primary Cell Drug Sensitivity Screening for Non-Small Cell Lung Cancer

• Customer Requirement: Evaluate efficacy differences of EGFR-TKI combination therapy in Asian populations.
• Protocol: Construct primary cell lines from 5 stage III patient samples, test osimertinib + chemotherapy combination.
• Results:

• IC50 of combination group was 3.2 times lower than single agent (p<0.01).
• Optimal synergistic combination screened (Combination Index=0.45), advancing customer to preclinical development stage.

8、Cooperation Advantages

• Full-cycle Support: One-stop service from primary line establishment → in vitro drug sensitivity → mechanism research.
• Efficient Response: Technical inquiries answered within 24 hours.
• Cost Optimization: Shared cell bank resources, reduce single-project startup cost by 30%.

9、FAQ

Q1: Is there a limit to the passage number of primary cells?

A: Usually stable for over 20 passages (genetic stability >95%).

10、Laboratory Highlights

• GMP-grade Class 10,000 clean environment, CR technology ensures cell viability.
• Simulates tumor microenvironment, improves drug sensitivity prediction accuracy.
• Processes 500+ samples daily, supports large-scale screening.

View More

11、Contact Us

Consult Now

• 📧Email: 3691125803@qq.com
• 📞Tel: +86 18802035152
• 🌐Online Form: Free Protocol Design

Limited Resources

• 📥Download Primary Tumor Cell Drug Sensitivity Screening Guide
• 💡Laboratory Virtual Tour: Panoramic VR tour of BSL-2 facilities.